

**Friday, March 26, 2021**  
**9:00 am CT-12:00 am CT**



## Musculoskeletal Tumor Society

“Connecting Our World to Push the Field Forward”

### General Information

#### Description

The focus of the upcoming Specialty Day will be on advances in musculoskeletal oncology around the world. With presenters from 6 continents, attendees will have the opportunity to learn the cutting-edge science, surgical techniques, and innovative technologies moving our field forward. Attendees will see different approaches to the challenges faced in orthopaedic oncology, and with interactive sessions, will contribute to collaborative solutions.

#### Educational Objectives

Upon completion of this session, attendees should be able to:

- Be aware of cutting-edge sarcoma research being performed in North America, Europe and Asia.
- Recognize different approaches to complex surgical cases.
- Identify new medical, non-surgical options for giant cell tumor of bone, tenosynovial giant cell tumor, and sarcoma.
- Understand the FDA approval process for new therapeutics and differences between device approval and drug approval.
- Develop an awareness of the difference organizations representing us (MSTS, EMSOS, ISOLS), the different roles each organization plays, and the potential collaborations in promoting education.

#### Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Orthopaedic Surgeons and the Musculoskeletal Tumor Society. The American Academy of Orthopaedic Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

#### Disclosure

Each faculty member in this Specialty Day Meeting has been asked to disclose if he or she (of their spouse/partner) has received something of value from a commercial company or institution, which relates directly or indirectly to the subject of their presentation. An indication of the participants disclosure appears after his or her name as well as the commercial company or institution that provides the support.

The AAOS and the MSTS does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author's participation in the course.

#### Disclaimer

The material presented at this Specialty Day Meeting has been made available by the MSTS for educational purposes only. This material is not intended to represent the only, or necessarily the best, methods or procedures appropriate for the medical situations discussed, but rather is intended to present an approach, view, statement or opinion of the faculty, which may be helpful to others who face similar situations.

The Musculoskeletal Tumor Society disclaims any and all liability for injury or other damages resulting to any individual attending a course and for all claims, which may arise out of the use of the techniques demonstrated there in by such individuals, whether these claims shall be asserted by a physician or any other person.

#### Program Committee Leadership

**Pietro Ruggieri, MD, PhD, Program Chair**  
**Nicholas M. Bernthal, MD, Vice Chair**  
**David M. King, MD, Member-at-Large**

<b>9:00 am – 9:05 am</b>	<b>Welcome</b> <i>Carol D. Morris, MD, MSTS President</i> <i>Pietro Ruggieri, MD, PhD, Program Chair</i>
<b>9:05 am – 9:45 am</b>	<b>Session I: State of Research</b>
	<b>Moderators:</b> <i>Pietro Ruggieri, MD, PhD</i> <i>and Wakenda K. Tyler, MD, MPH</i>
9:05 am – 9:15 am	Biomedical Research in the USA <i>Francis J. Hornicek, MD</i>
9:15 am – 9:25 am	Biomedical Research in Europe <i>Panayiotis J. Papagelopoulos, MD</i>
9:25 am – 9:35 am	Biomedical Research in Asia <i>Hiroyuki Tsuchiya, MD, PhD</i>
9:35 am - 9:45 am	What's New: Basic Science in Musculoskeletal Oncology <i>John H. Healey, MD, FACS</i>
<b>9:45 am – 10:35 am</b>	<b>Session II: MSTS Research Committee Special Session: Critical Issues &amp; Update on Emerging Drugs</b>
	<b>Moderators:</b> <i>David M. King, MD and Odion T. Binitie, MD</i>
9:45 am – 9:55 am	MSK Drug Targets, MSK Tumors, & FDA Approval Process <i>Rosanna Wustrack, MD</i>
9:55 am – 10:05 am	Bisphosphonates, Denosumab and Beyond <i>David D. Greenberg, MD</i>

10:05 am – 10:15 am	CSF-1 Receptor Blockers: Failures, Success, & Side Effects <i>Brooke M. Crawford, MD</i>	<b>11:15 am – 11:47 am</b>	<b>Session III: Education in Musculoskeletal Oncology – The role of International Societies in Promoting Education</b>
10:15 am – 10:25 am	(5) Immune Checkpoint Regulators: Failures, Successes, & Side Effects <i>Joseph H. Schwab, MD</i>		<b>Moderators:</b> <i>Franklin H. Sim, MD and Nicholas Bernthal, MD</i>
10:25 am – 10:35 am	Discussion and Questions	11:15 am – 11:23 am	The Role of MSTs <i>R. Lor Randall, MD, FACS</i>
<b>10:35 am – 10:55 am</b>	<b>Achieving Equilibrium</b> <b>Moderators:</b> <i>Patrick P. Lin, MD and Peter S. Rose, MD</i>	11:23 am – 11:31 am	The Role of EMSOS in Europe <i>Andreas Leithner, MD</i>
<b>10:35 am – 10:45 am</b>	<b>The Best and Worst Thing About My Job</b> <i>Michelle Ghert, MD, FRCSC</i>	11:31 am – 11:39 am	The Intercontinental Role of ISOLS <i>Mark T. Scarborough, MD</i>
<b>10:45 am – 10:55 am</b>	<b>Balancing Research and Clinical Care</b> <i>Parker Gibbs, Jr., MD</i>	11:39 am – 11:47 am	Discussion and Questions
10:55 am – 11:15 am	<b>New Technologies – Innovative Techniques Moderators:</b> <i>Peter Ferguson, MD and Emily E. Carmody, MD</i>	11:47 am – 12:00 am	Final Remarks <i>Pietro Ruggieri, MD, PhD and Nicholas M. Bernthal, MD</i>
10:55 am – 11:05 am	Minimally Invasive Endo-Pelvis Reconstruction for Metastatic Cancers <i>Francis Young Lee, MD, PhD</i>		
11:05 am – 11:15 am	Navigation in Musculoskeletal Oncology: An Update <i>David Joyce, MD</i>		